• Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

    1 month ago - By San Diego Biotechnology

    SAN DIEGO--Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced topline results for the TORREY...
    Read more ...